Pricing Log in Create free account
Friday 6 November 2026 Export LFCR’s income statement to Excel — free account

Lifecore Biomedical, Inc.

LFCR Healthcare Drug Manufacturers Specialty & Generic

Lifecore Biomedical, Inc.’s revenue for fiscal 2025 (year ended May 2025) was $128.9 million, roughly unchanged from fiscal 2024.

Revenue
−18.6%
EPS
−1,700.0%
Free cash flow
+27,684.0%
Total debt
+15.3%

Quarter to September 2026, against a year earlier

6.37 0.03 −0.47%
Market cap
$242.6M
P/E
0.0×
Fwd P/E
−6.4×
Dividend yield
—
F-score
3/9
Altman Z
0.12
Beneish M
−3.15
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 9.45%

Capital & Financial Ratios $m

Size
Market Cap 242.59
Revenue ttm 113.79
Net income ttm (51.23)
Free cash flow ttm 11.22
Net debt Q (23.03)
Valuation
P/E 0.00
Forward P/E (6.35) (negative: loss-making)
Price / sales 2.13
Forward P/S Powerpack
Price / FCF 36.27
Price / book 0.00
Financial health
Current ratio Q 3.84 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q 0.33
Growth
Revenue growth Q −18.60% (below 0%: shrinking)
Operating income growth Q +70.85% (above 0%: growing)
EPS, this year +42.91% (at or above 15%: strong)
EPS, next year A +40.69% (at or above 15%: strong)
Revenue, next year A −5.72% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +10.00%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.6×, against a ten-year median of 2.5×; over the ten years it ranged from −6.1× in 2021 to 68.9× in 2021.
P/S against its own 10 years 74.79%
10-year low 10-year high
EV/Sales against its own 10 years 77.25%
10-year low 10-year high
EV/FCF against its own 10 years 65.61%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 19 8 8 23
Receivables 29 27 29 —
Inventory 41 40 32 28
Other 5 4 7 10
94 81 86 85
2023 2024 2025 Q'26
Payables 22 16 8 9
ST’ Debt 1 1 — —
Other — — — —
39 39 30 22

Compound Annual Growth %

10y 5y 3y
Sales (13.34%) (4.24%) 5.02%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (14.23%) (27.14%) (18.56%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.17 Actual −0.19

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q1 FY26 −0.30 −0.29 Beat by 0.01
Q4 FY25 −0.14 −0.16 Miss by 0.02
Q1 FY26 −0.24 −0.43 Miss by 0.19
Q2 FY26 −0.17 −0.19 Miss by 0.02

EPS $

Aug Nov Feb May Year
’26 — — — — —
’25 (0.53) (0.25) (0.42) (0.06) (1.27)
’24 (0.35) 0.39 0.43 (0.20) 0.33
’23 (0.37) (0.43) (1.20) (1.19) (3.32)
’22 (0.32) (1.30) (0.44) (1.24) (3.96)
’21 (0.38) (0.45) (0.19) (0.10) (1.10)
’20 (0.16) (0.23) (0.39) (0.52) (1.31)
Fiscal quarters ending in the months shown.

Revenue $m

Aug Nov Feb May Year
’26 31 — — — —
’25 25 33 35 36 129
’24 25 30 36 38 128
’23 24 22 27 31 103
’22 42 43 37 (11) 111
’21 136 131 45 (210) 101
’20 139 143 153 (274) 160
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Aug Nov Feb May Year
’26 2 — — — —
’25 (1) (6) 1 5 0
’24 (8) 1 (8) 9 0
’23 (1) (2) (15) (2) (17)
’22 1 (5) (22) (1) (23)
’21 17 1 11 6 16
’20 (5) (9) (4) (13) (17)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Aug Nov Feb May Year
’26 0 — — — —
’25 (4) (9) (3) 3 (7)
’24 (13) (3) (24) 6 (18)
’23 (4) (3) (29) (9) (39)
’22 (6) (10) (39) (12) (51)
’21 17 7 12 (8) 4
’20 (15) (16) (24) (17) (41)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to May

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 477 470 524 558 160 101 111 103 128 129 114 (13.5%) 122 131 156 +6.5%
Gross margin, % 14.00 16.86 14.94 14.53 24.61 38.60 35.11 27.10 32.63 31.27 27.38 +17.3 pt
EBT (20) 14 16 4 (31) (30) (21) (64) 10 (39) (71) +7.8%
EBT margin, % (4.13) 3.02 3.13 0.65 (19.15) (29.53) (18.59) (61.90) 7.42 (30.01) (62.19) (25.9) pt
Net income (11) 11 25 0 (38) (32) (117) (100) 12 (39) (51) +14.5%
Per share, $
Per share, $ Revenue 17.63 17.22 19.04 19.66 5.49 3.44 3.78 3.45 4.21 3.70 3.01 (15.9%)
Earnings (0.42) 0.39 0.91 0.01 (1.31) (1.10) (3.96) (3.32) 0.39 (1.27) (1.99) +13.0%
Cash flow 0.77 1.09 0.72 0.56 (0.58) 0.56 (0.77) (0.58) 0.01 (0.01) 0.30 n/m
Capex (1.46) (0.84) (1.22) (1.57) (0.83) (0.42) (0.98) (0.72) (0.60) (0.18) 0.00 (20.6%)
Free cash flow (0.70) 0.25 (0.50) (1.00) (1.42) 0.14 (1.74) (1.30) (0.60) (0.19) 0.30 (13.4%)
Book value 7.85 8.36 9.17 9.53 7.92 6.92 2.98 1.17 1.77 1.36 (0.59) (17.7%)
Shares, m 27 27 28 28 29 29 29 30 30 35 38 +2.8%
Valuation, ×
Valuation, × P/E 0.00 35.77 15.62 781.10 0.00 0.00 0.00 0.00 14.75 0.00 0.00 84.7
P/S 0.66 0.81 0.74 0.50 1.97 3.38 2.52 2.38 1.39 1.82 2.13 1.6
P/B 1.47 1.67 1.54 1.04 1.37 1.68 3.09 0.00 15.73 190.30 0.00 21.8
EV/Sales 0.76 0.92 0.87 0.77 3.16 5.29 3.84 3.80 2.49 2.86 3.56 2.5
EV/FCF (11.52) 55.76 (27.38) (10.16) (7.01) 19.00 (6.32) (8.46) (9.26) (69.88) 60.69 (7.5)
Cash, $m
Cash, $m Operating cash flow 21 30 20 16 (17) 16 (23) (17) 0 0 11 n/m
Capex (40) (23) (33) (44) (24) (12) (29) (21) (18) (6) (5) (18.3%)
Free cash flow (19) 7 (14) (28) (41) 4 (51) (39) (18) (7) 11 (11.0%)
Balance, $m
Balance, $m Working capital 30 30 9 (4) (7) 46 (60) 55 42 55 63 +7.1%
Net debt 51 48 70 148 190 193 147 147 141 144 (23) +12.1%
Shareholders’ equity 212 228 253 270 231 203 88 35 54 47 (22) (15.3%)
Returns, %
Returns, % ROA (3.38) 3.02 6.51 0.09 (7.20) (6.19) (30.02) (37.70) 4.73 (17.98) (32.36) (14.6) pt
ROIC (4.89) 3.32 2.63 0.82 (3.84) (1.39) (3.14) (7.46) (2.83) (5.64) 0.00 (0.7) pt
ROE (5.38) 4.81 10.33 0.16 (15.24) (14.89) (80.32) (238.21) 339.11 (701.27) 178.69 (695.9) pt
People
People Employees 552 670 710 736 796 905 689 459 524 406 — (3.4%)
Revenue/emp, $m 0.86 0.70 0.74 0.76 0.20 0.11 0.16 0.22 0.24 0.32 — (10.5%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to May 2025 · latest quarter Sep 2026 · fundamentals updated 4 Nov 2026

Lifecore Biomedical, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
EBS Emergent Biosolutions Inc. $300.8M — (loss-making) — (loss-making) −52.40% (below 0%: shrinking) n/m +1,892.98% (above 0%: growing) 26.55% (33.91%) Compare
CGC Canopy Growth Corporation $283.5M — (loss-making) — (loss-making) +12.41% (above 0%: growing) n/m −117.60% (below 0%: shrinking) 27.40% (27.24%) Compare
ANIK Anika Therapeutics Inc. $258.7M — (loss-making) 599× +15.56% (above 0%: growing) n/m +61.58% (above 0%: growing) 65.15% 9.06% Compare
BIOA BioAge Labs, Inc. $254.3M — (loss-making) — (loss-making) −85.49% (below 0%: shrinking) n/m −92.81% (below 0%: shrinking) 100.00% (12,554.03%) Compare
LFCR Lifecore Biomedical, Inc. $242.6M — (loss-making) — (loss-making) −18.60% (below 0%: shrinking) n/m +27,684.00% (above 0%: growing) 26.96% (3.53%)
SIGA Siga Technologies Inc. $213.4M — (loss-making) 60.8× −49.45% (below 0%: shrinking) −66.00% (below 0%: shrinking) −75.95% (below 0%: shrinking) 57.17% 33.91% Compare
ADCT ADC Therapeutics SA $209.4M — (loss-making) — (loss-making) +2.17% (above 0%: growing) n/m +50.98% (above 0%: growing) 87.80% (132.03%) Compare
GLAS Glass House Brands Inc. $172.7M — (loss-making) — (loss-making) −1.24% (below 0%: shrinking) n/m −123.36% (below 0%: shrinking) 33.54% (6.37%) Compare
AKBA Akebia Therapeutics, Inc. $117.9M — (loss-making) — (loss-making) −37.20% (below 0%: shrinking) n/m −94.20% (below 0%: shrinking) 82.76% (31.06%) Compare
Median of peers $233.8M — — −19.22% — −84.38% 61.16% (29.15%)

All 84 Drug Manufacturers Specialty & Generic stocks →

Pay and ownership Proxy statement filed 24 April 2026

Ownership

Directors and executive officers, together 32.68% of the votes
Legion Partners Asset Management, LLC 17.27% of the votes
Christopher S. Kiper 17.27% of the votes
Wynnefield Capital, Inc. 14.31% of the votes
Nelson Obus 14.31% of the votes
Greenhaven Road Investment Management, LP 9.65% of the votes
325 Capital 8.15% of the votes
22NW, LP 7.88% of the votes
BlackRock, Inc 5.07% of the votes
LW Capital Management 5.07% of the votes
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Lifecore Biomedical, Inc. (LFCR) Latest News

4 Nov

Impact 3 · · GlobeNewswire

23 Oct

Impact 3 · · Insider Monkey

7 Oct

Impact 3 · · GlobeNewswire

28 Sep

Impact 4 · · GlobeNewswire

2 Sep

Impact 3 ·

17 Aug

Impact 3 ·

12 Aug

Impact 4 · · The Motley Fool transcript

6 Aug

Impact 3 · · Moby transcript

5 Aug

Impact 4 ·
Impact 3 · · MarketBeat transcript
Impact 3 ·

28 Jul

Impact 3 ·

15 Jul

Impact 3 ·

30 Jun

Impact 3 ·

15 Jun

Impact 4 ·

28 May

Impact 3 · · Simply Wall St.

6 May

Impact 4 · · MarketBeat
Impact 4 ·

27 Apr

Impact 4 · · Insider Monkey

26 Mar

Impact 3 · · GlobeNewswire

23 Mar

Impact 4 · · GlobeNewswire

20 Mar

Impact 4 · · MarketBeat

16 Mar

Impact 4 · · GuruFocus.com
Impact 4 · · MarketBeat
Impact 3 · · GlobeNewswire

4 Mar

Impact 4 · · GlobeNewswire

16 Jan

Impact 4 · · Insider Monkey

18 Dec

Impact 4 · · GlobeNewswire

17 Dec

Impact 4 · · GlobeNewswire

16 Dec

Impact 3 · · GlobeNewswire
stockrow.com/LFCR · Data as of Nov 4, 2026 · For information only; not investment advice. · © 2026 stockrow.com